Seattle Genetics, Inc. (SGEN)
(Delayed Data from NSDQ)
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
Pfizer's Mylotarg Recommended by FDA Advisory Committee
by Zacks Equity Research
Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).
Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.
Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU
by Zacks Equity Research
Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.
Seattle Genetics (SGEN) Reports Positive Data for Adcetris
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).
Seattle Genetics Halts Phase III Study on Leukemia Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
Seattle Genetics Reports Updated Results on Cancer Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME).
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.
New Strong Sell Stocks for April 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
by Joseph Lu
Immunomedics, Inc. (IMMU) stock soared in midday trading Thursday following the stop on the company's deal with Seattle Genetics (SGEN) after the lawsuit filed by Immunomedics' largest investor, venBio Select Advisor LLC, reported by The Street.
Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that the FDA has lifted the clinical hold on two phase I trials of its candidate, vadastuximab talirine (SGN-CD33A; 33A).
Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Seattle Genetics (SGEN)
by Brian Hamilton
Seattle Genetics recently reported both a top and bottom line miss, and reduced 2017 sales expectations.
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
by Zacks Equity Research
Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.
Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold
by Zacks Equity Research
Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.
Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
by Arpita Dutt
Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.
Bristol-Myers Reports Data from Opdivo Combination Studies
by Zacks Equity Research
Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.
5 Biotech Stocks to Bet on This Earnings Season
by Zacks Equity Research
The happening biotech sector should be a good bet for investors.